Bormioli Pharma, a provider of comprehensive packaging solutions for injectable drugs, announced robust growth in its North American business in 2022, with sales increasing more than 40% year-over-year.

The growth in North America was matched by strong sales gains in the company’s markets worldwide, reflecting Bormioli’s multimillion dollar investments in expanding its capabilities as a provider of comprehensive packaging solutions for injectable drugs.

“For almost 200 years, we have been leading the field of molded glass manufacturing and now we have expanded those capabilities to tubular glass vials designed for injectable drugs and vaccines,” said Andrea Lodetti, Bormioli Pharma CEO. “Our proud history is matched by our current passion for innovation in the provision of innovative comprehensive packaging solutions for drug makers. As a single supplier of all the components of the injection drug kit, we can offer a wide variety of cost-effective, flexible solutions tailored to the customer’s needs, while also pursuing an ambitious agenda to greatly increase the sustainability of all our operations.”

Bormioli added: “Our multi-faceted commitments are driven by two major factors – the supply chain issues from the continuing shortage of glass packaging for injectable drugs and the stark reminders of the inescapable dangers of ongoing climate change.”

In anticipation of its upcoming 200th anniversary, Bormioli Pharma launched “50-in-5,” a program designed to achieve 50% of sustainable raw materials in its pharmaceutical packaging production by 2025. According to the company, “50-in-5” is a project impacting the entire manufacturing footprint.

In addition, the company has been strengthening and expanding its industrial platform, with investments of more than 50 million euros to date that will be matched by similar investments over the next three years.

Strategies include increasing the percentage of recycled materials throughout the production process and adopting carbon capture and other green materials for container closure components and seals.

In a statement, the company said that the U.S. glass bottle market is dealing with continuing supply issues for injectable glass packaging as a result of lingering effects of the COVID-19 pandemic and resulting supply chain disruptions.

The company invested in strengthening its tubular glass vials capabilities through advanced machinery, while upgrading its platform for molded glass, and expanding clean-room capabilities to produce rubber stoppers.